DOCSLIB.ORG

Oxford® Policy Update Bulletin: June 2015 Oxford

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oxford® Policy Update Bulletin: June 2015 Oxford Oxford June 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health Revised care professionals may not seek or collect payment from a An existing policy has been reviewed and revisions have been made to member for services not covered by the applicable benefit plan the clinical coverage criteria and/or documentation review requirements unless first obtaining the member’s written consent, Replaced acknowledging that the service is not covered by the benefit plan An existing policy has been replaced with a new or different policy and that they will be billed directly for the service. Retired A complete library of Oxford® Medical and Administrative The procedural codes and/or services previously outlined in the policy are Policies is available at OxfordHealth.com > Providers > no longer being managed or are considered to be proven/medically Tools & Resources > Medical Information > Medical and necessary and are therefore not excluded as unproven/not medically Administrative Policies. necessary services, unless coverage guidelines or criteria are otherwise documented in another policy Note: The absence of a policy does not automatically indicate or imply Tips for using the Policy Update Bulletin: coverage. As always, coverage for a service or procedure must be From the table of contents, click the policy title to be determined in accordance with the member’s benefit plan and any directed to the corresponding policy update summary. applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence From the policy updates table, click the policy title to view a supporting the safety and effectiveness of a medical technology prior to complete copy of a new, updated, or revised policy. rendering a coverage determination. 2 Oxford® Policy Update Bulletin: June 2015 Oxford Oxford® Medical and Administrative Policy Updates In This Issue Clinical Policy Updates Page NEW Brand Antidepressants - Effective July 1, 2015 ................................................................................................................................................... 18 Eloctate™ (Antihemophilic Factor (Recombinant), FC Fusion Protein) for Connecticut Lines of Business, and New Jersey Individual Plans - Effective July 1, 2015 ................................................................................................................................................................................................... 18 Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome - Effective Sept. 1, 2015 ....................................................................... 20 Genetic Testing - Effective July 1, 2015 ............................................................................................................................................................. 20 UPDATED Ablative Treatment for Spinal Pain - Effective June 1, 2015.................................................................................................................................. 22 Blepharoplasty, Blepharoptosis and Brow Ptosis Repair - Effective June 1, 2015 ..................................................................................................... 24 Cardiology Procedures Requiring Precertification for CareCore National Arrangement - Effective July 1, 2015 ............................................................. 24 Computerized Dynamic Posturography - Effective July 1, 2015 ............................................................................................................................. 26 Epidural Steroid and Facet Injections for Spinal Pain - Effective July 1, 2015 .......................................................................................................... 27 Fetal Aneuploidy Testing Using Cell-Free Fetal Nucleic Acids in Maternal Blood - Effective July 1, 2015 ...................................................................... 29 Gait Analysis - Effective July 1, 2015 ................................................................................................................................................................ 29 Glaucoma Surgical Treatments - Effective June 1, 2015 ...................................................................................................................................... 31 In Utero Fetal Surgery - Effective June 1, 2015 .................................................................................................................................................. 31 Injectable Chemotherapy Drugs: Application of NCCN Clinical Practice Guidelines - Effective July 1, 2015.................................................................. 32 Manipulative Therapy - Effective June 1, 2015 .................................................................................................................................................... 35 Obstructive Sleep Apnea Treatment - Effective June 1, 2015 ................................................................................................................................ 38 Obstructive Sleep Apnea Treatment - Effective July 1, 2015 ................................................................................................................................. 41 Occipital Neuralgia and Headache Treatment - Effective June 1, 2015 ................................................................................................................... 44 Prolotherapy for Musculoskeletal Indications - Effective June 1, 2015 .................................................................................................................... 45 Radiation Therapy Procedures Requiring Precertification For CareCore National Arrangement - Effective July 1, 2015 .................................................. 45 Radiology Procedures Requiring Precertification for CareCore National Arrangement - Effective July 1, 2015 .............................................................. 47 Temporomandibular Joint Disorders - Effective July 1, 2015 ................................................................................................................................. 48 Vaccines - Effective July 1, 2015 ...................................................................................................................................................................... 49 REVISED Assisted Administration of Clotting Factors and Coagulant Blood Products - Effective July 1, 2015 ............................................................................ 51 Clotting Factors and Coagulant Blood Products - Effective July 1, 2015 .................................................................................................................. 53 Cosmetic and Reconstructive Procedures - Effective July 1, 2015 .......................................................................................................................... 58 Diabetic Insulins - Effective July 1, 2015 ........................................................................................................................................................... 59 3 Oxford® Policy Update Bulletin: June 2015 Oxford Oxford® Medical and Administrative Policy Updates In This Issue Diabetes Medications - Effective July 1, 2015 ..................................................................................................................................................... 60 Drug Coverage Criteria - New and Therapeutic Equivalent Medications - Effective July 1, 2015 ................................................................................
Load more

Recommended publications
  • Formulary and Prescribing Guidelines
    Formulary and Prescribing Guidelines SECTION 1: TREATMENT OF DEPRESSION Section 1. Treatment of depression 1.1 Introduction This guidance should be considered as part of a stepped care approach in the management of depressive disorders. Antidepressants are not routinely recommended for persistent sub-threshold depressive symptoms or mild depression but can be considered in these categories where there is a past history of moderate or severe depression, initial presentation of sub-threshold depressive symptoms for at least 2 years, and persistence of either mild or sub-threshold depression after other interventions1 have failed. The most current NICE guidance should be consulted wherever possible to obtain the most up to date information. For individuals with moderate or severe depression, a combination of antidepressant medication and a high intensity psychological intervention (CBT or IPT) is recommended. When depression is accompanied by symptoms of anxiety, usually treat the depression first. If the person has an anxiety disorder and co-morbid depression or depressive symptoms, consider treating the anxiety first. Also consider offering advice on sleep hygiene, by way of establishing regular sleep and wake times; avoiding excess eating, avoiding smoking and drinking alcohol before sleep; and taking regular physical exercise if possible. Detailed information on the treatment of depression in children and adolescents can be found in section 12. Further guidance on prescribing for older adults and for antenatal/postnatal service users can be found in section 11 and section 20, respectively. 1.2 Approved Drugs for the treatment of Depression in Adults For licensing indications, see Annex 1 Drug5 Formulation5 Comments2,3,4 Caps 20mg, 60mg Selective serotonin reuptake inhibitor (SSRI) Fluoxetine Liquid 20mg/5ml 1st line SSRI (based on acquisition cost) Tabs 10mg, 25mg, 50mg Amitriptyline Tricyclic (TCA).
    [Show full text]
  • Duloxetine for Chronic Pain Relief
    Patient Information Leaflet Duloxetine for Chronic Pain Relief Produced By: Chronic Pain Service April 2014 Review due April 2017 1 If you require this leaflet in another language, large print or another format, please contact the Quality Team, telephone 01983 534850, who will advise you. Duloxetine ( Cymbalta ) is a medicine used to relieve chronic pain and treat low mood. It is often helpful for nerve-related pain or pain sensitivity (also called central sensitisation ). It has a different way of relieving pain than standard pain killers and is often prescribed in combination. If used for pain other than diabetes-related neuropathic pain it is formally used outside it’s product license as per individual decision by your pain specialist/doctor. As it affects the central nervous system in complex ways, the effect often takes a while to be felt and requires regular intake . We recommend a trial of at least four weeks to judge the effect. If good, it should be taken on a regular long-term basis; if there is no distinct relief it should be discontinued after the trial period. If you suffer with seizures/epilepsy, glaucoma and poorly controlled high blood pressure, Duloxetine should be used with caution and at a lower dose (up to 60mg per day). The most common side effect is drowsiness/dizziness therefore it is best time to take it in the evening. There are many other possible side effects, but most are uncommon, rare or very rare (please take a look at the product leaflet) We suggest that you avoid driving for at least 2 days after starting or increasing the dose of this medication.
    [Show full text]
  • Milnacipran for Pain in Fibromyalgia in Adults
    Milnacipran for pain in fibromyalgia in adults (Review) Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 10 http://www.thecochranelibrary.com Milnacipran for pain in fibromyalgia in adults (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 9 Figure1. ..................................... 10 Figure2. ..................................... 12 Figure3. ..................................... 13 Figure4. ..................................... 14 Figure5. ..................................... 18 DISCUSSION ..................................... 21 AUTHORS’CONCLUSIONS . 22 ACKNOWLEDGEMENTS . 23 REFERENCES ..................................... 23 CHARACTERISTICSOFSTUDIES . 27 DATAANDANALYSES. 38 Analysis 1.1. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 1 At least 30% pain relief. 39 Analysis 1.2. Comparison 1 Milnacipran 100 mg/day versus placebo, Outcome 2 PGIC ’much improved’ or ’very much improved’.................................... 40 Analysis 1.3. Comparison
    [Show full text]
  • Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults
    Draft Comparative Effectiveness Review Number xx Adverse Effects of First-line Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy. Contract No. 290-2015-00012I Prepared by: Will be included in the final report Investigators: Will be included in the final report AHRQ Publication No. xx-EHCxxx <Month, Year> ii Purpose of the Review To assess adverse events of first-line antidepressants in the treatment of major depressive disorder in adults 65 years or older. Key Messages • Acute treatment (<12 weeks) with o Serotonin norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), but not selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine) led to a greater number of adverse events compared with placebo. o SSRIs (citalopram, escitalopram and fluoxetine) and SNRIs (duloxetine and venlafaxine) led to a greater number of patients withdrawing from studies due to adverse events compared with placebo o Details of the contributing adverse events in RCTs were rarely reported to more clearly characterize what adverse events to expect.
    [Show full text]
  • Cymbalta (Duloxetine Hcl) Prior Authorization of Benefits Form
    Cymbalta (Duloxetine HCl) Prior Authorization of Benefits Form CONTAINS CONFIDENTIAL PATIENT INFORMATION Complete form in its entirety and fax to: Prior Authorization of Benefits Center at 844-512-9005 for retail pharmacy or 844-512-7027 for medical injectable. 1. Patient information 2. Physician information Patient name: _________________________________ Prescribing physician: _______________________________ Patient ID #: __________________________________ Physician address: _________________________________ Patient DOB: _________________________________ Physician phone #: _________________________________ Date of Rx: ___________________________________ Physician fax #: ____________________________________ Patient phone #: _______________________________ Physician specialty: _________________________________ Patient email address: __________________________ Physician DEA: ____________________________________ Physician NPI #: ___________________________________ Physician email address: ____________________________ 3. Medication 4. Strength 5. Directions 6. Quantity per 30 days Cymbalta (Duloxetine HCl) ______________________ _____________________ Specify: ________________________ 7. Diagnosis: ____________________________________________________________________________________ 8. Approval criteria: (Check all boxes that apply. Note: Any areas not filled out are considered not applicable to your patient and may affect the outcome of this request.) Major depressive disorder (MDD), depressive disorder or dysthymia: □ Yes □ No Patient has
    [Show full text]
  • Medication Guide Duloxetine Delayed-Release Capsules, USP (Doo-LOX
    Medication Guide Duloxetine Delayed-Release Capsules, USP (doo-LOX-e-teen) Read this Medication Guide before you start taking duloxetine delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression, other serious mental illnesses, and suicidal thoughts or actions? 1. Duloxetine delayed-release capsules and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness). 3. How can I watch for and try to prevent suicidal thoughts and actions? • Pay close attention to any changes in mood, behavior, actions, thoughts, or feelings, especially sudden changes. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled.
    [Show full text]
  • Commentary USP 40–NF 35
    Commentary USP 40–NF 35 November 1, 2016 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP website at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected] Page 1
    [Show full text]
  • Medication Guide Cymbalta
    1 Medication Guide Cymbalta® [sim-BALL-tah] (duloxetine delayed-release capsules) Read this Medication Guide before you start taking Cymbalta® and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression, other serious mental illnesses, and suicidal thoughts or actions? 1. Cymbalta and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness). 3. How can I watch for and try to prevent suicidal thoughts and actions? • Pay close attention to any changes in mood, behavior, actions, thoughts, or feelings, especially sudden changes. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
    [Show full text]
  • Duloxetine (Cymbalta)
    DULOXETINE (CYMBALTA) Duloxetine (Cymbalta) is approved by the FDA for treatment of major depressive disorder; management of pain associated with diabetic neuropathy. It is useful in treating chronic neuropathic pain from other causes. Duloxetine comes in 30 and 60 mg tablets. The standard dose is 60 mg per day. To be certain you can tolerate the medication, the starting dose is 30 mg daily. You should stay at that dose for 14 days before increasing. It is possible but unlikely that you will get any benefit from this low dose. If you do not have problems with side-effects, increase the dose to 60 mg once a day. Duloxetine can be taken any time of the day with or without a meal. At 60 mg per day, you should know within 30 days if the medication is going to help. You should NOT take Duloxetine if: You are allergic to duloxetine hydrochloride or other ingredients in it. You currently or have recently taken monoamine oxidase inhibitor (MAOI). You have uncontrolled narrow-angle glaucoma. You are taking Mellaril® (thioridazine). The most common side effect when taking duloxetine was nausea. For most people, the nausea was mild to moderate, and usually subsided within one to two weeks. Other common side effects included (listed in order of frequency): Constipation, Decreased appetite, Dizziness, Dry mouth, Fatigue, Increased sweating, Loss of strength or energy, Sleepiness. Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.
    [Show full text]
  • 181013929019.Pdf
    Archivos Españoles de Urología ISSN: 0004-0614 [email protected] Editorial Iniestares S.A. España Pérez Martínez, Francisco Carlos; Vela Navarrete, Remigio; Castilla Reparaz, Carlos COMPARATIVE EFFECTS OF CLOMIPRAMINE AND DULOXETINE ON DETRUSOR AND STRIATED SPHINCTER FUNCTION IN MALE AND FEMALE RABBITS. Archivos Españoles de Urología, vol. 59, núm. 8, octubre, 2006, pp. 839-848 Editorial Iniestares S.A. Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=181013929019 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative International Section Arch. Esp. Urol., 59, 8 (839-848), 2006 COMPARATIVE EFFECTS OF CLOMIPRAMINE AND DULOXETINE ON DETRUSOR AND STRIATED SPHINCTER FUNCTION IN MALE AND FEMALE RABBITS. Francisco Carlos Pérez Martínez1, Remigio Vela Navarrete1 and Carlos Castilla Reparaz2. 1Departamento de Urología, Universidad Autónoma de Madrid. Fundación Jiménez Díaz. Madrid. 2Departamento de Cirugía Experimental y Experimentación Animal. Fundación Jiménez Díaz. Madrid. Spain. Summary.- OBJECTIVE: Serotonin and norepinephri- cystometrogram. Simultaneously, SAS-EMG was recor- ne systems are involved in the neural control of lower ded through electromyography electrodes placed in the urinary tract function. The aim of this study was to com- perianal striated muscle. pare the response on striated anal sphincter electromyo- RESULTS: Cystometric parameters: Under irritative condi- graphic (SAS-EMG) activity and cystometric parameters, tions, 2 mg./Kg. clomipramine in male rabbits and 1 or when duloxetine and clomipramine were intravenously 2 mg./Kg. in female rabbits, depending on the dose, administrated.
    [Show full text]
  • Treating Painful Diabetic Peripheral Neuropathy: an Update MATTHEW J
    Treating Painful Diabetic Peripheral Neuropathy: An Update MATTHEW J. SNYDER, DO, and LAWRENCE M. GIBBS, MD, Saint Louis University Family Medicine Residency, Belleville, Illinois TAMMY J. LINDSAY, MD, Saint Louis University Family Medicine Residency, St. Louis, Missouri Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who are treated in the office setting and significantly affects quality of life. It typically causes burning pain, paresthesias, and numbness in a stocking-glove pattern that progresses proximally from the feet and hands. Clinicians should carefully consider the patient’s goals and functional status and potential adverse effects of medication when choosing a treat- ment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the only medications approved by the U.S. Food and Drug Administration for treating this disorder. Based on current practice guidelines, these medica- tions, with gabapentin and amitriptyline, should be considered for the initial treatment. Second-line therapy includes opioid-like medications (tramadol and tapentadol), venlafaxine, desvenlafaxine, and topical agents (lidocaine patches and capsaicin cream). Isosorbide dinitrate spray and transcutaneous electrical nerve stimulation may provide relief in some patients and can be considered at any point during therapy. Opioids and selective serotonin reuptake inhibitors are optional third-line medications. Acupuncture, traditional Chinese medicine, alpha lipoic acid, acetyl-L-carnitine, primrose oil, and electromagnetic field application lackhigh-quality evidence to support their use. (Am Fam Physi- cian. 2016;94(3):227-234. Copyright © 2016 American Academy of Family Physicians.) CME This clinical content ainful diabetic peripheral neuropa- glucose control in patients with type 1 dia- conforms to AAFP criteria thy (DPN) occurs in approximately betes significantly reduced the risk of devel- for continuing medical education (CME).
    [Show full text]
  • Oxford® Policy Update Bulletin: October 2015 Oxford
    Oxford October 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]